Search Results

You are looking at 41 - 50 of 74 items for :

  • "chemotherapy administration" x
  • All content x
Clear All
Full access

Nina N. Sanford, Todd A. Aguilera, Michael R. Folkert, Chul Ahn, Brandon A. Mahal, Herbert Zeh, Muhammad S. Beg, John Mansour, and David J. Sher

. However, the NCDB is the largest US cancer registry, capturing 70% of incident cancers, and it also includes comprehensive treatment information, including details regarding chemotherapy administration, and is therefore one of the most robust databases for

Full access

Andrew G. Robinson, Xuejiao Wei, William J. Mackillop, Yingwei Peng, and Christopher M. Booth

chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population . J Thorac Oncol 2010 ; 5 : 1529 – 1535 . 27. Baunemann Ott CL Ratna N Prayag R . Survival and treatment patterns in elderly patients with

Full access

Maria Dans, Thomas Smith, Anthony Back, Justin N. Baker, Jessica R. Bauman, Anna C. Beck, Susan Block, Toby Campbell, Amy A. Case, Shalini Dalal, Howard Edwards, Thomas R. Fitch, Jennifer Kapo, Jean S. Kutner, Elizabeth Kvale, Charles Miller, Sumathi Misra, William Mitchell, Diane G. Portman, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Jennifer Temel, Roma Tickoo, Susan G. Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman, and Jillian L. Scavone

be more aggressive than what is supported by current evidence. Generally, Medicare patients with cancer with a poor prognosis have received highly intensive EOL care. 33 Furthermore, chemotherapy administration late in the disease course, including

Full access

Davinia S.E. Seah, Ines Vaz Luis, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin, and Harold J. Burstein

the shortest duration of chemotherapy for each line. Patients with HER2-amplified tumors also experienced the longest overall survival. Finally, the median time from last chemotherapy administration until death was found to be 37 days, with 18% of

Full access

Brigette A. Davis, Jenerius A. Aminawung, Maysa M. Abu-Khalaf, Suzanne B. Evans, Kevin Su, Rajni Mehta, Shi-Yi Wang, and Cary P. Gross

Rabinovitch R . 21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profile . J Clin Oncol 2016 ; 34 : 1995 – 2002 . 24

Full access

Vivek Verma, Amy C. Moreno, Waqar Haque, Penny Fang, and Steven H. Lin

patients who warrant combined-modality therapy are at high risk of distant failure, for which early chemotherapy administration is most necessary. Based on these unavoidable biases in this and other similar NCDB studies, 5 , 6 we posit a conservative

Full access

Ali Mokdad, Travis Browning, John C. Mansour, Hao Zhu, Amit G. Singal, and Adam C. Yopp

finding. Time of treatment, which was defined as the time definitive management of HCC was initiated (ie, date of surgical resection, first chemotherapy administration, or date of locoregional therapy). Time of death or last follow-up. Figure 1

Full access

Oxana Palesh, Arianna Aldridge-Gerry, Ayhan Ulusakarya, Elisabet Ortiz-Tudela, Lucile Capuron, and Pasquale F. Innominato

evaluate the sleep-wake rhythm compared with sleep logs under ambulatory conditions. 79 The individual assessment of circadian system status before chemotherapy administration could be a valuable tool for screening of patients with disrupted rhythms. Thus

Full access

Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber, and Anusha Kalbasi

Results Program. Accessed July 21, 2019. Available at: https://seer.cancer.gov/ 31. Movva S , von Mehren M , Ross EA , . Patterns of chemotherapy administration in high-risk soft tissue sarcoma and impact on overall survival . J Natl Compr Canc

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

recurrence risk score is an important determinant in chemotherapy administration for patients with node-negative, HR+/HER2–, early-stage breast cancer per the NCCN Guidelines. 11 A few limitations should be noted. First, information was lacking on the